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Abstract
Somatic hypermutation (SHM) of immunoglobulin genes is initiated by activation-induced cytidine deaminase (AID) in
activated B cells. This process is strictly dependent on transcription. Hence, cis-acting transcriptional control elements have
been proposed to target SHM to immunoglobulin loci. The Mus musculus Igk locus is regulated by the intronic enhancer (iE/
MAR) and the 39 enhancer (39E), and multiple studies using transgenic and knock-out approaches in mice and cell lines have
reported somewhat contradictory results about the function of these enhancers in AID-mediated sequence diversification.
Here we show that the M. musculus iE/MAR and 39E elements are active solely as transcriptional enhancer when placed in
the context of the IGL locus in Gallus gallus DT40 cells, but they are very inefficient in targeting AID-mediated mutation
events to this locus. This suggests that either key components of the cis-regulatory targeting elements reside outside the
murine Igk transcriptional enhancer sequences, or that the targeting of AID activity to Ig loci occurs by largely species-
specific mechanisms.
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Introduction
Antibody diversity is hallmark of vertebrate immune function,
and is generated during two distinct stages of B cell development.
First, the assembly of immunoglobulin (Ig) gene segments by V(D)J
recombination gives rise to functional antigen receptor genes and
the primary antibody repertoire. Secondary diversification is
achieved through the processes of somatic hypermutation (SHM),
Ig gene conversion (GCV) and class switch recombination (CSR)
to generate high-affinity antibodies with improved effector
function. All three processes, SHM, GCV and CSR, are initiated
by activation-induced cytidine deaminase (AID) [1,2,3]. This
enzyme deaminates cytosine residues within single-stranded DNA
that is transiently generated during transcription of Ig genes [4].
The resulting G:U mismatches are resolved by direct replication or
by DNA repair mechanisms involving uracil DNA glycosylase,
mismatch repair factors, and error-prone DNA polymerases [5].
GCV copies sequence information from upstream pseudogenes
into the variable region of the Ig gene resulting in ‘‘templated’’
nucleotide changes, whereas SHM creates individual ‘‘non-
templated’’ point mutations. SHM occurs across all jawed
vertebrates, while GCV has been only observed in selected
species, including G. gallus and Oryctolagus cuniculus [6]. Although
the end products of SHM and GCV differ, it is widely believed
that the molecular principles that govern their AID-dependent
initiation phase are identical [7]. As AID is highly mutagenic,
specific mechanisms are in place to restrict its activity to Ig gene
loci [8]. Nonetheless, it is worth noting, that non-Ig genes can
become targets of widely distributed low levels of SHM [9], as AID
interacts with components of the general transcription machinery
[10]. The focusing of SHM/GCV to Ig genes is thought to be
mediated by cis-regulatory elements, and given the mechanistic
link between transcription and SHM/GCV/CSR, transcriptional
enhancers were considered to be strong candidates [11,12].
We and others recently reported first evidence for the existence
of such cis-regulatory targeting elements in the context of the
endogenous G. gallus IGL gene locus, and based on their location it
was conceivable that they reside within transcriptional enhancers
[13,14,15]. The situation with respect to the identity and location
of such targeting elements in the M. musculus Igk gene is less clear.
This locus contains three enhancers: the intronic enhancer (iE/
MAR) [16], the 39 enhancer (39E) [17], and the downstream
enhancer (Ed) [18]. Transgenic studies indicated that the iE/MAR
and 39E elements are necessary for SHM of Igk transgenes [19].
In contrast, knock-out mice in which the iE/MAR or the 39E were
deleted individually showed normal or only modestly (2- to 2.5-
fold) reduced levels of SHM, respectively [20]. The latter could be
readily explained by a corresponding drop in Igk transcription in
these mice [20]. This suggested that neither of these enhancers
individually is necessary for SHM, and hence that there might be
functional redundancy. Simultaneous deletion of both enhancers
resulted in a block of B cell development as Vk-Jk rearrangement
was inhibited [21], and hence the SHM status could not be
addressed. A recent report, however, showed that the presence of
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respective GFP reporter transgenes in DT40 cells [22]. In this
case, the E-box motifs (CAGGTG) within these enhancers were
critical for targeting, but did not play a role in transcription.
To resolve these controversial observations regarding the
importance of the iE/MAR and 39E for targeting of SHM to Ig
loci, we performed cross-complementation experiments in which
the endogenous cis-regulatory elements essential for transcription
and targeting in the IGL locus of DT40 cells were replaced with
the respective M. musculus enhancers. Here we report that the M.
musculus enhancers are fully competent to drive transcription in the
context of the G. gallus IGL locus, but are unable to support high-
levels of SHM/GCV, neither individually nor in combination.
Our findings suggest that transcriptional enhancer function, even
that of Ig enhancers, does not correlate with targeting of AID
activity. This finding raises the possibility that additional binding
sites important for efficient targeting in the M. musculus Igk locus
reside outside the defined iE/MAR and 39E transcription
enhancers. An alternative and even more intriguing explanation
could be species specific targeting mechanisms for AID activity.
Results
In our previous study, the DM cell line in which the VJ and C
exons are joined showed robust SHM/GCV at levels comparable
to that of wild-type cells [13]. The newly created VJC exon
allowed us to generate gene-targeting constructs that target solely
the ‘‘active’’ rearranged and not the ‘‘silent’’ unrearranged allele,
and thus DM cells served as the parental line for subsequent
deletion studies. In particular, we generated a DT40 cell line
(DME6K) which completely lacks transcription and SHM/GCV
in its IGL gene (Fig. 1) [13]. This phenotype was caused by a
deletion of large portions of non-coding DNA from this locus
including the 39 regulatory region (39RR) that harbors transcrip-
tional enhancers and targeting elements for AID-mediated
sequence diversification. Importantly, SHM/GCV was still
occurring normally in the Ig heavy (IGH) chain locus of these
cells, indicating that these cells were still competent for SHM/
GCV. Thus, the DME6K background represents a good model
system to test the functional properties of M. musculus Igk
enhancers in these AID-mediated processes in the context of an
endogenous IGL locus.
To determine the functional properties of the M. musculus iE/
MAR with respect to transcription and SHM, iE/MAR knock-in
DT40 cell lines were created in the context of the DME6K IGL
genotype starting from DM cells (Fig. 1). The IGL locus in the
ieMar DT40 cells matches that of DME6K, but in addition
harbors the iE/MAR fragment from the M. musculus Igk locus.
Two independent clones with this genotype were generated by
gene targeting, ieMar 14.4 and ieMar 25.2, and their identities
were confirmed by Southern blot analysis (Fig. 2A). The
puromycin-resistance selection cassette was subsequently removed
using a cell-permeable Cre-recombinase. To test whether the M.
musculus iE/MAR element provides transcriptional enhancer
activity in the context of the G. gallus IGL locus, we measured
the steady state IGL transcript levels by Northern blot analysis.
While the DME6K line carries no endogenous G. gallus IGL
enhancer and therefore shows no evidence of transcription [13],
IGL transcripts were four-fold lower albeit readily detectable in the
ieMar lines compared to the parental DM line (Fig. 2B and 2C).
They are, however, still at the 59% of the levels found in wild-type
cells (Fig. 1C), and importantly such reduced levels were found to
be sufficient to support robust SHM/GCV (see clones DE and
DME in [13]). This indicated that the M. musculus iE/MAR
sequences are active as transcriptional enhancers in the IGL locus
of DT40 cells, but clearly less strong than the cognate G. gallus IGL
enhancer.
To test whether the iE/MAR enhancer is also sufficient to
recruit AID-mediated sequence diversification in this system,
twelve sub-clones of ieMar 14.4 and ieMar 25.2 were continuously
grown for four weeks, and their surface IgM phenotype was
assessed by flow cytometry at weeks two, three, and four. All cells
started as IgM
2 due to a premature stop codon in the VJ exon of
their IGL gene that was introduced during gene-targeting. A subset
of the GCV events leads to a reversion of this mutation, thereby
creating surface IgM
+ cells. In contrast to cultures of the parental
DM line which showed increasing percentages of IgM
+ cells over
time, IgM
+ cells remained undetectable in any of the 24 ieMar
sub-clones even after 4 weeks (Fig. 2D). As some of the GCV and
non-templated SHM events do not result in a reversion of the stop
Figure 1. Schematic representation of the IGL loci in individual DT40 lines. The rearranged allele of the IGL locus in the indicated cell lines is
drawn to scale. The leader (L), the VJ exon, constant region (C), and the CR1 retrotransposon (present in the published chicken genome as well as in
DT40 cells, S.D.F. unpublished) are shown as filled boxes. The putative matrix attachment region (MAR) and the 467 bp enhancer (Enh) are shown as
filled ovals. Elements that are present are shown in black, those that are deleted are in grey. The murine enhancer elements (iE/MAR and 3kE) in the
respective knock-in alleles are depicted as orange ovals.
doi:10.1371/journal.pone.0018955.g001
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PLoS ONE | www.plosone.org 2 April 2011 | Volume 6 | Issue 4 | e18955Figure 2. Functional analysis of the iE/MAR enhancer element. A) Schematic representation of the gene-targeting approach. The rearranged
IGL allele of the parental DM line, the intermediate ieMAR puro allele, and the final product, the IGL locus of the ieMar DT40 cells, are drawn to scale.
The targeting vector is shown with its homology arms, the iE/MAR (orange oval), the puromycin selection cassette (yellow box) and flanking loxP sites
(filled triangles), but the plasmid backbone is omitted for clarity. The restriction sites used for the Southern blot analyses are marked (A: AvrII, H:
HindIII, and S: SacI), and the probes for each step (P1 and P2, respectively) are shown as red lines above the locus. The asterisk in each Southern blot
marks the band that originates from the non-rearranged allele. B) Northern Blots were run using 10 mg of total RNA of wild-type (WT) DT40 cells and
each of the indicated cell lines, and hybridized sequentially with IGL and GAPDH probes. One representative example is shown. C) Steady-state
transcript levels of IGL were measured by Northern blot and normalized to those of GAPDH. The level in wild-type (WT) cells was arbitrarily set to one,
and each data point represents the average of at least four independent values per genotype. D) GCV was assessed by flow cytometry over four
weeks starting from single cell clones. The average percentage of IgM+ cells in a total of 24 subclones from two independent ieMar lines is shown at
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sequencing the VJ exon of the IGL locus at the end of the four
week culture. The mutation frequency of 0.363610
24 events/bp is
dramatically lower than that observed in the wild-type cells
(4.07610
24 events/bp, [13]), and is even below the background
level of our system (0.5610
24 events/bp, observed in AID-
deficient DT40 cells, [23]) (Fig. 2E). This suggests that the iE/
MAR is unable to support high levels of SHM/GCV in DT40
cells. One possibility is that these cells entirely lost their ability to
diversify their Ig genes. Thus we sequenced the IGH locus of our
ieMar cell lines at the four week time point as well. Importantly,
the IGH gene showed robust evidence of AID-mediated sequence
diversification (4.07610
24 events/bp) similar to that observed in
the parental DM cells (6.22610
24 events/bp, [13]), suggesting that
AID activity was unaltered in these knock-in clones (Fig. 2E).
Based on the flow cytometry and the supporting DNA sequencing
data, we conclude that the M. musculus iE/MAR enhancer is
indeed unable to support efficient SHM/GCV of the DT40 IGL
locus (i.e. detectable by our experimental system) despite its ability
to act as a transcription enhancer. These findings are consistent
with the phenotype of iE/MAR knock-out mice that showed
largely unaltered SHM [20]. They are, however, in striking
contrast to the initial observations made by Betz et al. using
traditional Igk transgenes [19].
To determine whether the 39E enhancer is sufficient to support
SHM/GCV in our DT40 system, we generated knock-in clones
(3kE) in which the 39E enhancer replaced the cis-regulatory
elements of the G. gallus IGL locus. Again, the genotype of these
3kE lines were confirmed by Southern blot analyses (Fig. 3A). The
steady state IGL transcript levels were again four-fold reduced
compared to the DM line (Fig. 3B and 3C), comparable to what
we observed in our ieMar knock-in lines (Fig. 2C). This
corresponds to 77% of the IGL transcript levels in the wild-type
cells, and hence, as discussed above, might be sufficient to support
SHM/GCV. Furthermore, 3kE cultures showed no significant
population of IgM
+ cells, even over a growth period of four weeks
(Fig. 3D). Sequencing analysis revealed a mutation frequency of
0.393610
24 events/bp in the IGL gene of these cells (Fig. 3E),
comparable to that of 0.363610
24 events/bp seen in the ieMar
genotype, and again below the background of this experimental
system. Lastly, as expected, IGH diversification by SHM/GCV
was still ongoing in the 3kE lines (Fig. 3E), suggesting that the
absence of detectable AID-mediated sequence diversification in
the IGL gene is simply due to a lack of a targeting element in our
modified knock-in locus. This in turn infers, that when placed in
the IGL locus of DT40 cells, the 39E alone, just like the iE/MAR,
works largely as a transcriptional enhancer with no detectable
(based on the limit of our assays) targeting activity. This is again
consistent with previous reports of 39E-deficient mice, which were
characterized by reduced levels of Igk transcription and
correspondingly mild SHM defects [20].
To address the formal possibility that both enhancers act in
synergy to support AID-mediated diversification processes, double
enhancer knock-in (ieK) clones were generated by gene-targeting,
and verified by Southern blot analysis (Fig. 4A). Strikingly,
simultaneous presence of both M. musculus Igk enhancers
supported IGL transcript levels comparable to those observed in
the parental DM line (Fig. 4B and 4C). Culturing 24 sub-clones
continuously for four weeks resulted in a minimal increase in the
size of the IgM
+ cell populations, indicating a dramatic reduction
of GCV in the IGL locus of the ieK cells (Fig. 4D). To confirm this
observation, we performed sequence analysis of the IGL gene,
while the mutation frequency of 0.619610
24 events/bp was
higher than that observed in the individual enhancer knock-in
lines (0.393610
24 events/bp and 0.363610
24 events/bp, respec-
tively), it was still barely above the background of 0.5610
24
events/bp (Fig. 4E). To confirm that these clones did not exhibit a
general reduction of SHM/GCV due to reduced AID activity, the
IGH variable region was sequenced as well. This analysis revealed
clear evidence for levels of SHM/GCV comparable to those
observed in the parental cell line in this gene locus (Fig. 4E). This
suggests that even the presence of both M. musculus Igk enhancers,
the iE/MAR and the 39E, is not sufficient to support high levels of
AID-mediated sequence diversification in the context of the G.
gallus IGL locus. As the M. musculus enhancer sequences used here
were neither mutated nor truncated, they retained their native
CAGGTG E-box binding sites. Thus the presence of these binding
sites is not sufficient to efficiently target SHM/GCV at the robust
levels observed in wild-type DT40 cells.
Discussion
In summary, our results indicate that the iE/MAR and 39E are
active as transcriptional enhancers across species, as they are able
to support transcription of the IGL locus in the G. gallus DT40 B
cell line. Interestingly, however, they were unable to promote
SHM. One obvious possibility is that the M. musculus elements do
not work in the context of a G. gallus B cell nucleus. As both
elements are able to function independently and cooperatively as
transcriptional enhancers, we conclude that at least some of the
transcription factor binding sites important for driving Ig gene
transcription are utilized. Thus the species incompatibility of these
cis-regulatory sequences would be largely confined to those binding
site/DNA-binding factor pairs that are important for targeting
AID activity. This would imply a provocative model in which the
targeting of SHM to Ig loci involves species specific mechanisms.
SHM is evolutionarily conserved and is critical for Ig gene
diversification loci throughout the entire jawed vertebrate clade,
and hence the existence of species specific targeting elements
seems counterintuitive at first glance. Our data, however, are
consistent with such model.
An alternative explanation for the lack of AID-mediated
sequence diversification in the IGL gene of our knock-in lines is
that the M. musculus enhancer elements are not sufficient or very
inefficient in targeting SHM in general, which extends previous
reports that neither of these enhancers by itself is strictly required
for this process [20]. In this scenario, our observations imply that
the key cis-regulatory sequences essential for SHM targeting reside
in non-coding regions of the Igk locus outside these well
characterized transcriptional control elements. This model is fully
compatible with the idea that both transcriptional enhancers, the
iE/MAR and the 39E, are involved in SHM, and that high levels
of SHM activity require their functional interaction with the yet to
be discovered targeting element. One candidate for such targeting
element is the recently described Ed element, but its deletion had
only modest effects on SHM [24].
each time point. E) Mutation event frequencies in the IGL (filled bars) and IGH (open bars) loci were determined by sequencing the VJ or VDJ exon
from two independent subclones after four weeks of continuous culture. The background level of 0.5610–5 events/bp for this system was
determined in AID-deficient DT40 cells [23], and is shown as a dotted line. The data for wild type (WT) and DME6K were obtained from [13]. Asterisks
indicate p,0.005 in a Student’s t-test.
doi:10.1371/journal.pone.0018955.g002
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PLoS ONE | www.plosone.org 4 April 2011 | Volume 6 | Issue 4 | e18955Figure 3. Functional analysis of the 39E enhancer element. A) Gene-targeting scheme to generate the 3kE DT40 knock-in cell lines. The 3kE
element is represented as an orange oval, the restriction sites used for Southern Blot analyses are marked (B: BamHI, and S: SacI), and the Southern
blot probe (red line, P) used for genotyping is shown. For a description of all other elements, see legend to Fig. 1. The asterisk in each Southern blot
marks the band that originates from the non-rearranged allele. B) Northern Blots were run using 10 mg of total RNA of wild-type (WT) DT40 cells and
each of the indicated cell lines, and hybridized sequentially with IGL and GAPDH probes. One representative example is shown. C) Average
normalized steady-state transcript levels of IGL measured by Northern blot analyses obtained from at least four independent values per genotype.
The value for wild-type (WT) DT40 cells is arbitrarily set to one. D) GCV was quantified by flow cytometry over four weeks starting from single cell
Mouse Ig Kappa Enhancers do not Target SHM
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lab that three CAGGTG (E-box) sites within the M. musculus Igk
enhancers are sufficient to recruit SHM in DT40 cells [22]. The
fundamental differences between these studies are: (1) the use of a
sensitive GFP reporter-based transgenic system compared to our
knock-in approach using the endogenous Ig gene context
including the G. gallus Ig promoter, and (2) the sequencing of the
GFP genes from selected GFP
+ population (which may bias
towards individual cells with higher levels of mutation) compared
to the use of a bulk culture as source for genomic DNA. One
plausible explanation for the discrepancies is that the transgenic
system might emphasize the importance of the CAGGTG sites for
SHM, but does not quantitatively address the magnitude of their
role, as the double enhancer knock-in reported here showed only a
minimal effect on SHM. This is consistent with the observation that
E-box motifs are a common feature of genes that are transcribed in
activated B cells and mutated at frequencies that are at least 50-fold
lower than the cognate SHM target, the Ig genes, but still clearly
higher than the remainder of the genome [9]. Alternatively, one
could invoke the presence of putative negative regulatory elements
residing in the G. gallus IGL locus that actively suppress the targeting
activity of the M. musculus enhancers. While data in a recent study
suggest that such elements exist (compare fragments M and N in
Figure 3 of [14]), this DNA sequence is not present in any of our
knock-in clones. In addition, non-coding sequences from Ig loci of
otherspecies areable tosupport normallevelsofSHM/GCV inour
system (N.R.K and S.D.F, unpublished data), and thus we consider
the possibility of negative regulatory elements less likely. But at the
current point in time we do not have any experimental data that
would rule out this explanation.
In summary, our results are consistent with a model in which the
traditional transcriptional Ig enhancers primarily function to support
high levels of transcription of Ig genes, while the support of AID-
mediated sequence diversification depends on additional mutation
enhancer elements. The molecular mode of action of such cis-
regulatory elements remains to be elucidated. A recent report
suggests that the transcription elongation factor Spt5 acts an adaptor
to recruit AID to actively transcribed gene loci and that AID is
therefore more broadly distributed than previously anticipated [10].
ThissuggeststhatthetargetingelementsforSHMrenderAIDhighly
active, and/or recruit error-prone DNA repair. Our model system
represents a useful tool to reveal the identity of such cis-regulatory
sequences within the large amount of as of yet uncharacterized non-
coding DNA in Ig loci. But given the possibility of species specific
targeting mechanisms our approach might not be applicable to
elements from mammalian Ig loci. The identification of such cis-
regulatory elements will inturn set the stage for subsequent studies to
illuminate the underlying molecular mechanism of targeting.
Materials and Methods
Targeting constructs
The puromycin cassette of a modified pLoxPuro plasmid [25]
was inserted as a BamHI/BglII fragment into DME6K vector [13]
giving rise to the DME6K-BBHpuro plasmid. The iE/MAR and
39E M. musculus enhancers were amplified by PCR from a plasmid
(provided by Dr. F. Nina Papavasiliou, The Rockefeller Univer-
sity) and M. musculus genomic DNA using Phusion polymerase
(New England Biolabs, Ipswich, MA) and primer pairs EiKr: 59-
acttggatccaactgctcactggatggtgg-39/EiKf: 59-acttggatccagcttaatgta-
tataatcttttag-39 and 3kEr: 59-gtacggatccagctcaaaccagcttaggcta-39/
3kEf: 59-gtacggatccctagaacgtgtctgggccccatgaa-39, respectively. The
enhancers were subsequently inserted as BamHI fragments into
the BamHI site of DME6K-BBHpuro to obtain the final targeting
vectors. For the plasmid carrying both enhancers, the iE/MAR
enhancer was first inserted as a BamHI/BglII fragment (amplified
using primer pair EiKf/BglII-EiKr: 59-acttagatctaactgctcactg-
gatggtgg-39) into DME6K-BBHpuro and the 39E was subsequently
inserted as a BamHI fragment.
Tissue culture and gene-targeting
DT40 cells (provided by Dr. Jean-Marie Buerstedde, GSF,
Munich, [26]) were grown in RPMI 1640 (Mediatech, Manassas,
VA) supplemented with 10% fetal bovine serum (Invitrogen,
Carlsbad, CA), 1% chicken serum (Invitrogen), 10 mM HEPES,
2 mM L-glutamine, and penicillin/streptomycin (Mediatech) at
41uC in 5% CO2. Transfections were performed in 4 mm cuvettes
using 25–30 mg of linearized plasmid DNA in a Bio-Rad Gene
Pulser(Bio-Rad,Hercules,CA) at 580 V,25 mF,and ‘ V resistance.
Stable transfectants were selected with 0.5 mg/ml puromycin
(Invitrogen), and clones with targeted integrations were identified
by Southern blot analyses. The Southern blot probes were amplified
from genomic DNA by PCR using primer pair erar4: 59-
agcacagaacaggcacgtgct-39/QG11R: 59-gacgttgatgtgggacgatgtg-39
(for probe P, see Figs. 2, 3, 4) or CCLF1: 59-cccaccgtcaaaggag-
gagctg-39/CHVLR1: 59-cagtagatctttagcactcggacctcttcagg-39 (for
probe P2, see Figure 2), and body-labeled with [a-
32P]dCTP using
the NEBlot kit (New England Biolabs). Blots were hybridized
overnight, and bands were visualized using a Phosphorimager
(Molecular Dynamics). Cre-mediated deletion of puromycin resis-
tance cassettes was done using a cell-permeable His-Tat-NLS-Cre
fusion protein (where NLS is "nuclear localization signal") as
described previously [13]), and confirmed bySouthern blot analyses.
Mutation analysis
Gene conversion and mutation analysis was performed as
described previously [13]. Briefly, single cell clones were obtained
by limiting dilution and cultured continuously for four weeks.
Surface IgM was analysis by flow cytometry using a PE-conjugated
anti-chicken IgM Ab (Southern Biotechnology, Birmingham, AL).
VJ region sequences were amplified and sequence from the
genomic DNA of two individual subclones (one per independent
clone for each genotype) at the end of the four week period.
Mutation frequencies were calculated as the ratio of the number of
mutation events (both, templated as well as non-templated) to the
total number of base pairs sequenced.
Gene expression analysis
Total RNA was isolated using RNABee (Tel-Test, Friendswood
TX) according to the manufacturer’s protocol, and transcript levels
were determined by Northern blot analyses. Probes for IGL and
GAPDH were amplified by PCR using primer pairs CCLF1: 59-
cccaccgtcaaaggaggagctg-39/CHVLR1: 59-cagtagatctttagcactcg-
gacctcttcagg-39 and CHGAPDHF: 59-accagggctgccgtcctctc-39/
CHGAPDHR: 59-ttctccatggtggtgaagac-39. Signals were detected
using a Storm PhosphorImager (Amersham Biosciences, Piscataway
NJ) and quantified using ImageQuant (Molecular Dynamics).
clones. The average percentage of IgM+ cells from 12 subclones of each of the two independent 3kE lines is shown. E) Mutation event frequencies in
the IGL (filled bars) and IGH (open bars) loci were determined by sequencing from two independent subclones after four weeks of continuous culture.
The data for wild type (WT) and DME6K were obtained from [13]. Asterisks indicate p,0.005 in a Student’s t-test.
doi:10.1371/journal.pone.0018955.g003
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PLoS ONE | www.plosone.org 6 April 2011 | Volume 6 | Issue 4 | e18955Figure 4. Analysis of double Igk enhancer knock-in DT40 cells. A) Gene-targeting scheme with the murine iE/MAR and 3kE shown as orange
ovals, for a detailed description of all elements see Fig. 1. The restriction sites are marked (A: AvrII, and B: BamHI), and the red line above the locus
denotes the Southern blot probe (P). The asterisk in each Southern blot marks the band that originates from the non-rearranged allele. B) Northern
Blots were run using 10 mg of total RNA of wild-type (WT) DT40 cells and each of the indicated cell lines, and hybridized sequentially with IGL and
GAPDH probes. One representative example is shown. C) Normalized steady-state transcript levels of IGL were determined by Northern blots analysis.
The level in wild-type cells is arbitrarily set to one, and an average of at least four data points obtained for each genotype is shown. D) Average
percentagesofIgM
+cells(twelve subclonesperindicateclone) ateach timepointareshownforeach genotype.E)Mutationeventfrequencies intheIGL
(filled bars) and IGH (open bars) loci were determined by sequencing of the VJ or VDJ exon from two independent subclones of the ieK DT40 cells after
four weeks of continuous culture. The data for wild type (WT) and DME6K were obtained from [13]. Asterisks indicate p,0.005 in a Student’s t-test.
doi:10.1371/journal.pone.0018955.g004
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